These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Transplant-associated thrombotic microangiopathy: theoretical considerations and a practical approach to an unrefined diagnosis. Young JA; Pallas CR; Knovich MA Bone Marrow Transplant; 2021 Aug; 56(8):1805-1817. PubMed ID: 33875812 [TBL] [Abstract][Full Text] [Related]
44. Rare variants in complement system genes associate with endothelial damage after pediatric allogeneic hematopoietic stem cell transplantation. Leimi L; Koski JR; Kilpivaara O; Vettenranta K; Lokki AI; Meri S Front Immunol; 2023; 14():1249958. PubMed ID: 37771589 [TBL] [Abstract][Full Text] [Related]
45. Risk factors and appropriate therapeutic strategies for thrombotic microangiopathy after allogeneic HSCT. Matsui H; Arai Y; Imoto H; Mitsuyoshi T; Tamura N; Kondo T; Kanda J; Ishikawa T; Imada K; Ueda Y; Toda Y; Anzai N; Yago K; Nohgawa M; Yonezawa A; Tsunemine H; Itoh M; Yamamoto K; Tsuji M; Moriguchi T; Takaori-Kondo A; Blood Adv; 2020 Jul; 4(13):3169-3179. PubMed ID: 32658984 [TBL] [Abstract][Full Text] [Related]
46. Efficacy and Safety of Eculizumab in the Treatment of Transplant-Associated Thrombotic Microangiopathy: A Systematic Review and Meta-Analysis. Zhang R; Zhou M; Qi J; Miao W; Zhang Z; Wu D; Han Y Front Immunol; 2020; 11():564647. PubMed ID: 33552043 [TBL] [Abstract][Full Text] [Related]
47. Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab. Jodele S; Dandoy CE; Lane A; Laskin BL; Teusink-Cross A; Myers KC; Wallace G; Nelson A; Bleesing J; Chima RS; Hirsch R; Ryan TD; Benoit S; Mizuno K; Warren M; Davies SM Blood; 2020 Mar; 135(13):1049-1057. PubMed ID: 31932840 [TBL] [Abstract][Full Text] [Related]
48. Vascular endothelium as 'novel' target of graft-versus-host disease. Tichelli A; Gratwohl A Best Pract Res Clin Haematol; 2008 Jun; 21(2):139-48. PubMed ID: 18503982 [TBL] [Abstract][Full Text] [Related]
49. Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults. Jodele S; Davies SM; Lane A; Khoury J; Dandoy C; Goebel J; Myers K; Grimley M; Bleesing J; El-Bietar J; Wallace G; Chima RS; Paff Z; Laskin BL Blood; 2014 Jul; 124(4):645-53. PubMed ID: 24876561 [TBL] [Abstract][Full Text] [Related]
50. Transplantation-associated thrombotic microangiopathy isolated to a congenital anomaly of the lung. Kummen RT; Cuvelier GD; Stefanovici C; Perry AM; Higgins R; Yanofsky R; Lum Min SA; Wall DA Pediatr Transplant; 2017 Feb; 21(1):. PubMed ID: 27882637 [TBL] [Abstract][Full Text] [Related]
51. Hematopoietic transplant-associated thrombotic microangiopathy: case report and review of diagnosis and treatments. Chapin J; Shore T; Forsberg P; Desman G; Van Besien K; Laurence J Clin Adv Hematol Oncol; 2014 Sep; 12(9):565-73. PubMed ID: 25654478 [TBL] [Abstract][Full Text] [Related]
52. Incidence, Predictors, and Outcomes of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation. Lewis C; Kim HT; Roeker LE; Cutler C; Koreth J; Nikiforow S; Armand P; Gootpu M; Romee R; Glotzbecker B; Nageshwar P; Antin JH; Alyea EP; Richardson P; Soiffer RJ; Ho VT Biol Blood Marrow Transplant; 2020 Mar; 26(3):529-539. PubMed ID: 31678537 [TBL] [Abstract][Full Text] [Related]
53. Underdiagnosed veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) as a major cause of multi-organ failure in acute leukemia transplant patients: an analysis from the EBMT Acute Leukemia Working Party. Bazarbachi AH; Al Hamed R; Labopin M; Halaburda K; Labussiere H; Bernasconi P; Schroyens W; Gandemer V; Schaap NPM; Loschi M; Jindra P; Snowden J; Wu D; Guffroy B; Rovira M; Chantepie SP; Poiré X; Lopez-Corral L; Nikolousis M; Pelosini M; Ciceri F; Baron F; Bazarbachi A; Corbacioglu S; Savani BN; Peric Z; Nagler A; Carreras E; Mohty M Bone Marrow Transplant; 2021 Apr; 56(4):917-927. PubMed ID: 33208915 [TBL] [Abstract][Full Text] [Related]
54. Risk factors for transplant-associated thrombotic microangiopathy and mortality in a pediatric cohort. Schoettler M; Lehmann LE; Margossian S; Lee M; Kean LS; Kao PC; Ma C; Duncan CN Blood Adv; 2020 Jun; 4(11):2536-2547. PubMed ID: 32516415 [TBL] [Abstract][Full Text] [Related]
55. [Changes in diagnostic criteria of thrombotic microangiopathy after stem cell transplantation]. Horváth O; Prohászka Z; Kállay K; Kassa C; Stréhn A; Csordás K; Sinkó J; Kriván G Orv Hetil; 2017 Jul; 158(27):1043-1050. PubMed ID: 28670985 [TBL] [Abstract][Full Text] [Related]
58. Abnormal echocardiography 7 days after stem cell transplantation may be an early indicator of thrombotic microangiopathy. Dandoy CE; Davies SM; Hirsch R; Chima RS; Paff Z; Cash M; Ryan TD; Lane A; El-Bietar J; Myers KC; Jodele S Biol Blood Marrow Transplant; 2015 Jan; 21(1):113-8. PubMed ID: 25300868 [TBL] [Abstract][Full Text] [Related]
59. Distribution of Transplantation-Associated Thrombotic Microangiopathy (TA-TMA) and Comparison between Renal TA-TMA and Intestinal TA-TMA: Autopsy Study. Yamada R; Nemoto T; Ohashi K; Tonooka A; Horiguchi SI; Motoi T; Hishima T Biol Blood Marrow Transplant; 2020 Jan; 26(1):178-188. PubMed ID: 31491486 [TBL] [Abstract][Full Text] [Related]